This compound is primarily utilized in the field of targeted protein degradation, particularly in the development of proteolysis-targeting chimeras (PROTACs). It functions by recruiting specific proteins to E3 ubiquitin ligases, leading to their ubiquitination and subsequent degradation by the proteasome. This mechanism is especially valuable in cancer research, where it helps degrade oncogenic proteins that are otherwise difficult to target with traditional small-molecule inhibitors. Its structure includes a ligand for E3 ligase and a moiety that binds to the target protein, making it a versatile tool for studying disease-related proteins and developing potential therapeutic strategies. Additionally, its application extends to probing biological pathways and understanding protein function in cellular contexts.